ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

(1R,2S,3R,5S)-3-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(5-ethyl-tetrazol-2-yl)-cyclopentane-1,2-diol → 1-((R)-1-{6-(2,2-Diphenyl-ethylamino)-9-[(1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea

HRID 1641938
印刷

反応式

HRID 1641938 の反応式
N[C@@H]1CCN(C2N=C3C(N=CN3[C@@H]3C[C@H](N4N=NC(CC)=N4)[C@@H](O)[C@H]3O)=C(NCC(C3C=CC=CC=3)C3C=CC=CC=3)N=2)C1.Cl.[C:46]1([CH:52]([C:93]2[CH:98]=[CH:97][CH:96]=[CH:95][CH:94]=2)[CH2:53][NH:54][C:55]2[N:63]=[C:62]([N:64]3[CH2:68][CH2:67][C@@H:66]([NH:69][C:70]([NH:72][C:73]4[CH:74]=[N:75][CH:76]=[CH:77][CH:78]=4)=[O:71])[CH2:65]3)[N:61]=[C:60]3[C:56]=2[N:57]=[CH:58][N:59]3[C@@H:79]2[CH2:83][C@H:82]([N:84]3[N:88]=[N:87][C:86]([CH2:89][CH3:90])=[N:85]3)[C@@H:81]([OH:91])[C@H:80]2[OH:92])[CH:51]=[CH:50][CH:49]=[CH:48][CH:47]=1>>[C:93]1([CH:52]([C:46]2[CH:47]=[CH:48][CH:49]=[CH:50][CH:51]=2)[CH2:53][NH:54][C:55]2[N:63]=[C:62]([N:64]3[CH2:68][CH2:67][C@@H:66]([NH:69][C:70]([NH:72][C:73]4[CH:74]=[N:75][CH:76]=[CH:77][CH:78]=4)=[O:71])[CH2:65]3)[N:61]=[C:60]3[C:56]=2[N:57]=[CH:58][N:59]3[C@@H:79]2[CH2:83][C@H:82]([N:84]3[N:88]=[N:87][C:86]([CH2:89][CH3:90])=[N:85]3)[C@@H:81]([OH:91])[C@H:80]2[OH:92])[CH:98]=[CH:97][CH:96]=[CH:95][CH:94]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

3

反応物 2

HCID 11650095(1R,2S,3R,5S)-3-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(5-ethyl-tetrazol-2-yl)-cyclopentane-1,2-diolHCID 667359671-((R)-1-{6-(2,2-Diphenyl-ethylamino)-9-[(1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea hydrochloride

生成物 1

HCID 667357771-((R)-1-{6-(2,2-Diphenyl-ethylamino)-9-[(1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea

実験手順

This compound is prepared from (1R,2S,3R,5S)-3-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(5-ethyl-tetrazol-2-yl)-cyclopentane-1,2-diol (Example 48), using a procedure analogues to that of 1-((R)-1-{6-(2,2-diphenyl-ethylamino)-9-[((1R,2S,3R,4S)-4-(5-ethyl-tetrazol-2-yl)-2,3-dihydroxy-cyclopentyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea hydrochloride (Example 104). After purification, the compound is partitioned between DCM and saturated NaHCO3 (aq). The organics are dried (MgSO4), filtered and reduced in vacuo to yield the title compound. MS (ES+) m/e 716.51 (MH+).

後処理

  1. customAfter purification
  2. customthe compound is partitioned between DCM and saturated NaHCO3 (aq)
  3. dry with materialThe organics are dried (MgSO4)
  4. filtrationfiltered

出典と根拠

ORDレコード
ord-478ae855e1884d1da2e2b4aa48445726
出典データセット
uspto-grants-2012_02
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08114877B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート